Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but severe immunological reaction to the non-replicable adenoviral vector-based COVID-19 vaccines. Extreme activation of platelets and the coagulation system leads to a high risk of death from venous or arterial thrombosis or secondary hemorrhage. Public and clinician awareness has reduced mortality of VITT by nearly 90%. The World Health Organization provided a guideline in July 2021 on diagnosis and management of VITT (also called thrombosis with thrombocytopenia syndrome, or TTS). Since July 2021, new, clinically relevant information has become available. This update has been summarized by the authors in an informal process with recommendations for low resource environments. We provide new available evidence on VITT to empower clinicians to recognize VITT early, then effectively diagnose and treat the disorder to reduce morbidity and mortality. We strongly encourage production of clear management pathways for primary care settings and hospital settings.

Automated summary

VITT is a rare but severe immunological reaction to non-replicable adenoviral vector-based COVID-19 vaccines, causing extreme activation of platelets and the coagulation system, increasing the risk of death. The World Health Organization provided guidelines for the diagnosis and management of VITT, and authors summarized new clinically relevant information with recommendations for low resource environments.